Review Article

Prognostic and Clinical Significance of Aspartate Aminotransferase-to-Lymphocyte Ratio Index in Individuals with Liver Cancer: A Meta-Analysis

Xiulan Peng,1 Yali Huang,1 Min Zhang,1 Yan Chen,2 Lihua Zhang,3 Anbing He,1 and Renfeng Luo4

1Department of Oncology, The Second Affiliated Hospital of Jianghan University, China
2Department of Neurology, Wuhan Fourth Hospital, Puai Hospital, Tongji Medical College, Huazhong University of Science and Technology, China
3Department of Neurosurgery, Wuhan Fourth Hospital, Puai Hospital, Tongji Medical College, Huazhong University of Science and Technology, China
4Department of Diagnostics, Jianghan University, China

Correspondence should be addressed to Xiulan Peng; pengxlwh@163.com

Received 20 June 2021; Revised 3 December 2021; Accepted 28 December 2021; Published 9 February 2022

Academic Editor: Young-Kug Kim

Copyright © 2022 Xiulan Peng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. This study was aimed at exploring the prognostic and clinicopathological roles of aspartate aminotransferase-to-lymphocyte ratio index (ALRI) in patients with hepatocellular carcinoma via a meta-analysis. Methods. The PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang, and VIP databases were comprehensively searched from inception to November 20, 2021. Pooled hazard ratio (HR) and corresponding 95% confidence interval (CI) were used to evaluate the relationship between ALRI and overall survival (OS) as well as progression-free survival (PFS) in patients with hepatocellular carcinoma. Odds ratio (OR) and the corresponding 95% CI were also used to investigate correlations between clinical factors and ALRI in patients with hepatocellular carcinoma. Results. A total of 3914 patients with hepatocellular carcinoma from eleven retrospective cohorts were included in this meta-analysis. The combined results revealed that patients with hepatocellular carcinoma with elevated ALRI tended to have unfavorable OS (HR 1.53 [95% CI 1.25–1.82]; P < 0.001). Pooled HRs revealed that high ALRI was an independent risk factor for inferior PFS in patients with hepatocellular carcinoma (HR 1.36 [95% CI 1.10–1.63]; P < 0.001). In addition, high ALRI was strongly associated with male sex (OR 1.32 [95% CI 1.02–1.70]; P = 0.035), presence of cirrhosis (OR 1.68 [95% CI 1.01–2.81]; P = 0.046), larger tumor size (OR 2.25 [95% CI 1.31–3.88]; P < 0.001), presence of portal vein tumor thrombus (OR 2.50 [95% CI 1.52–4.11]; P < 0.001), and distant metastasis (OR 1.72 [95% CI 1.05–2.82]; P = 0.031). Conclusion. Elevated ALRI in patients with hepatocellular carcinoma predicted inferior survival outcomes and was strongly associated with some important features of hepatocellular carcinoma.

1. Introduction

Hepatocellular carcinoma (HCC) is the most frequent cause of cancer-related death worldwide and ranks fifth in terms of incidence in the United States [1]. Unfortunately, the incidence of HCC continues to increase annually [2]. Recognized risk factors for HCC include hepatitis virus infection, alcohol-related cirrhosis, fatty liver disease, nonalcoholic fatty liver disease, obesity, diabetes, and various dietary exposures [3]. Because of the high rate of hepatitis B virus (HBV) infection among the Chinese population, the HCC causes heavy medical and economic burden in China, and China accounts for approximately 50% of HCC cases worldwide [4]. The prognosis of individuals with HCC is far from satisfactory partially due to the lack of accurate prognostic biomarkers. The primary role of prognostic indexes is to give an estimation of the aggressiveness of HCC on a case-by-case basis. The promising biomarkers related to HCC could...
be applied appropriately to stratify patients, thus enabling more accurate treatment allocation. Therefore, there is a highly urgent medical demand to identify reliable prognostic biomarkers, especially for HCC, that would be conducive to the design and development of optimal treatment regimens and improve the clinical outcomes of individuals with HCC.

Recent studies have demonstrated that inflammatory response plays an essential role in the progression and metastasis of HCC [5–7]. Therefore, a panel of serum biomarkers based on inflammation parameters from routine bloodwork, such as systemic immune-inflammation index (SII) [8], prognostic nutritional index (PNI) [9], platelet-to-lymphocyte ratio [10], and Integrated Liver Inflammatory Score [11], have been demonstrated to be efficient prognostic biomarkers for patients with cancer. The aspartate aminotransferase (AST) to-lymphocyte ratio index (ALRI) is a novel inflammatory index for HCC [12] and is derived from the ratio of AST to lymphocyte count. ALRI has been reported to be related to the survival of patients with HCC [13–23]; however, results have not been consistent across studies. Therefore, we conducted the current meta-analysis to determine the prognostic impact and clinical significance of ALRI in patients with HCC by aggregating all available data.

2. Methods

2.1. Search Strategy. This meta-analysis was prospectively enrolled in PROSPERO (ID: CRD42021238765, https://www.crd.york.ac.uk/PROSPERO/) and was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (i.e., PRISMA) statement [24]. The PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang, and VIP databases were comprehensively searched from inception to November 20, 2021. Search terms included “liver cancer,” “liver neoplasm,” “hepatocellular carcinoma,” “HCC” AND “aspartate aminotransferase/lymphocyte,” “aspartate aminotransferase-to-lymphocyte ratio index,” “aspartate aminotransferase to lymphocyte ratio,” and “ALRI.” Additionally, the references of relevant studies were manually screened to identify additional potentially eligible studies. The included studies were restricted to those published in English and Chinese.

2.2. Inclusion and Exclusion Criteria. Study inclusion criteria were as follows: primary HCC was the only cancer diagnosis; age ≥18 years; individuals with HCC were classified into two groups based on an ALRI cut-off value; investigation of the association between ALRI and overall survival (OS) or progression-free survival (PFS) among patients with HCC; and reported hazard ratio (HR) and corresponding 95% confidence interval (CI) for ALRI. Reviews, meta-analyses, letters, case reports, clinical studies without full text, or studies not reporting HR and 95% CI for ALRI were excluded.

2.3. Data Collection and Quality Evaluation. Two investigators (YH and MZ) independently reviewed the articles retrieved in the literature search and extracted the relevant data. Any disagreements were ultimately resolved by discussion with a third reviewer (RL). The following clinical information was extracted from the retrieved articles by LZ and YC: year of publication; author’s surname; study period; study design; staging criteria; age of participants; country of origin, sex; sample size; tumor stage; treatment plan; cut-off value for ALRI; selection of cut-off value; follow-up; and HR and 95% CI for ALRI. The HRs in this meta-analysis were derived from multivariate Cox analysis.

The quality of all included studies was assessed using the Newcastle–Ottawa Scale (NOS) [25]. The NOS rating generally ranges from 0 to 9, and studies with a score ≥7 were regarded to be of high quality.

2.4. Statistical Analysis. In this meta-analysis, all statistical analyses were performed using STATA version 15.0 (STATACorp LLC, College Station, TX, USA). The overall HRs and 95% CIs were calculated to determine the relationship between ALRI and OS or PFS in patients with HCC. Pooled ORs with 95% CIs were also calculated to investigate the correlation between ALRI and common clinical features of HCC. Cochran’s Q test combined with the I² test was used to assess the statistical heterogeneity across the included studies, with significant heterogeneity viewed as I² > 50%. A random-effect model was used for pooled data analysis when significant heterogeneity (i.e., I² > 50%) was observed; otherwise, a fixed effect model was used. Sensitivity analysis was used to assess the stability of the pooled ORs or HRs by sequentially excluding one study from the analysis. Begg’s test together with Egger’s test was used to explore for the presence of publication bias.

3. Results

3.1. Study Characteristics. The primary literature search retrieved 81 articles. After removing duplicate publications and reviewing the abstracts, only eleven clinical studies [13–23] that fulfilled the inclusion criteria were ultimately included in this meta-analysis. The process of the literature selection is presented in Figure 1. The eleven clinical studies included retrospective cohorts and were published between 2015 and 2021. Sample sizes ranged from 78 to 983, with a total of 3914. Interestingly, all eleven studies were performed in China. Three clinical trials were published in the Chinese language [18–20] and the remainder in English. The cut-off value for ALRI ranged from 18.734 to 86, with a mean value of 33.96. All eleven clinical studies reported the association between ALRI and OS, and only seven studies [18–20, 22, 23] demonstrated a correlation between ALRI and PFS. Regarding quality evaluation, only two studies [13, 15] scored 7 and nine studies scored 8; as such, all studies were regarded to be of high quality (Table S1). Detailed clinical information of the nine included studies are summarized in Table 1.

3.2. Pooled Analysis of the Association between ALRI and OS. A total of 3914 patients with HCC from eleven retrospective cohorts were included in this meta-analysis. Because of notable study heterogeneity (I² = 80.4% and P < 0.0001), the random-effect model was selected for the combined meta-
analysis. The combined results revealed that patients with HCC with elevated ALRI tended to have unfavorable OS (HR 1.53 [95% CI 1.25–1.82]; \( P < 0.001 \)) (Figure 2(a)). Owing to the presence of significant heterogeneity in the meta-analysis, subgroup analyses were performed based on a list of common clinical factors. As shown in Table 2, significant correlations between ALRI and inferior OS persisted in the subgroup analyses of treatment, staging criteria, sample size, ALRI cut-off value, cut-off selection, and NOS score.

F: female; M: male; NA: not available; TACE: transcatheter arterial chemoembolization; BCLC: Barcelona clinic hepatocellular carcinoma; AJCC: American Joint Committee on Cancer; NOS: Newcastle–Ottawa Scale; OS: overall survival; PFS: progression-free survival; ROC: receiver-operating characteristics curve. Age were presented as means; follow-up months were presented as median value, while “∗” was presented as means.

### 3.3. Pooled Analysis of the Correlation between ALRI and PFS

Seven studies including 2865 patients with HCC reported information addressing the relationship between ALRI and PFS. Because of the notable heterogeneity (\( I^2 = 81.8\% \) and \( P < 0.0001 \)), the random-effect model was selected for the combined meta-analysis. The overall results revealed a significant relationship between elevated ALRI and worse PFS among individuals with HCC (HR 1.53 [95% CI 1.25–1.82]; \( P < 0.001 \)) (Figure 2(b)). As shown in Table 2, remarkable relationships between high ALRI and unfavorable PFS persisted in the subgroup analyses of treatment, staging criteria, sample size, ALRI cut-off value, cut-off selection, and NOS score.

CI: confidence interval; HR: hazard ratio; NA: not available; TACE: transcatheter arterial chemoembolization; BCLC: Barcelona clinic hepatocellular carcinoma; AJCC: American Joint Committee on Cancer; NOS: Newcastle–Ottawa Scale; OS: overall survival; PFS: progression-free survival; ROC: receiver-operating characteristics curve.

### 3.4. Relationship between ALRI and Clinical Features

Based on the clinical characteristics reported in the eleven articles, the clinical significance of ALRI among patients with HCC was further analyzed. The overall OR and corresponding 95% CI were calculated using the STATA software to assess the associations between ALRI and selected clinical features.
## Table 1: Major features of eleven references included in this meta-analysis.

| Author year | County | Study period       | Study design   | Sample size | Age (years) | Sex (M/F)         | Staging criteria |
|-------------|--------|-------------------|----------------|-------------|-------------|-------------------|-----------------|
| He (2017)   | China  | 2007-2013         | Retrospective  | 241         | 50.3        | 210 (87%)/31 (13%) | Milan criteria   |
| Liu (2020)  | China  | 2011-2016         | Retrospective  | 206         | 53          | 160 (78%)/46 (22%) | AJCC 8th        |
| Jin (2015)  | China  | 1997-2008         | Retrospective  | 371         | NA          | 323 (87%)/48 (13%) | NA              |
| Yang (2015) | China  | 2009-2015         | Retrospective  | 189         | 53.4        | 161 (85%)/28 (15%) | BCLC            |
| Zhao (2019) | China  | 2009-2013         | Retrospective  | 429         | 54          | 392 (91%)/37 (9%)  | AJCC 7th        |
| Zheng (2019)| China  | 2011-2013         | Retrospective  | 78          | 60.12       | 67 (86%)/14 (11%)  | BCLC            |
| Suo (2019)  | China  | 1993-2010         | Retrospective  | 463         | 50.14       | 401 (87%)/62 (13%) | BCLC            |
| Qin (2019)  | China  | 2013-2017         | Retrospective  | 191         | 48.62       | 154 (81%)/37 (19%) | AJCC 8th        |
| Chen (2020) | China  | 2007-2016         | Retrospective  | 937         | 54          | 392 (91%)/37 (9%)  | NA              |
| Liao (2021) | China  | 2009-2016         | Retrospective  | 416         | 54.7        | 359 (86%)/57 (14%) | NA              |
| Wu (2021)   | China  | 2014-2017         | Retrospective  | 347         | NA          | 290 (83.6%)/57 (14%) | BCLC/ AJCC8th |

| Author year | Tumor stage | Treatment   | Cut-off value | Cut-off selection | Follow-up months | Survival analysis | NOS score |
|-------------|-------------|-------------|---------------|-------------------|-----------------|------------------|-----------|
| He (2017)   | Size <3; 3-5 cm | Surgical resection | 32 | Mean value | 54.2 | OS, PFS | 7        |
| Liu (2020)  | I-IV        | Surgical resection | 18.734 | ROC analysis | 35 | OS | 8        |
| Jin (2015)  | I-IV        | Surgical resection | 25.2 | ROC analysis | 20 | OS, PFS | 7        |
| Yang (2015) | A-C         | TACE        | 57 | R software | 30.2* | OS | 8        |
| Zhao (2019) | I-IV        | Palliative treatments | 86.3 | ROC analysis | NA | OS | 8        |
| Zheng (2019)| B-C         | TACE        | 22.82 | ROC analysis | 18.16* | OS, PFS | 8        |
| Suo (2019)  | 0-C         | Surgical resection | 25.2 | ROC analysis | 47.12 | OS, PFS | 8        |
| Qin (2020)  | I-III       | Surgical resection | 26.06 | ROC analysis | 32.4 | OS | 8        |
| Chen (2020) | A           | Surgical resection | 26.6 | X-tile | 48.8 | OS, PFS | 8        |
| Liao (2021) | I-III       | Surgical resection | 22.6 | ROC analysis | 36.7 | O, PFS | 8        |
| Wu (2021)   | Size≤5; >5 cm | Surgical resection | 31 | ROC analysis | 45 | OS, PFS | 8        |

Figure 2: Forest plots of the hazard ration evaluating the association between the ALRI and survival in liver cancer individuals. (a) Overall survival and (b) progression-free survival.
### Table 2: Subgroup analysis of pooled HRs and 95% CIs between ALRI and OS and PFS in hepatocellular carcinoma.

| Variables                        | No. of studies | No. of patients | Effects model | HR (95% CI)          | P     | $I^2$ (%) | P     |
|----------------------------------|----------------|-----------------|---------------|----------------------|-------|----------|-------|
| **OS**                           |                |                 |               |                      |       |          |       |
| Total                            | 11             | 3914            | Random        | 1.53 (1.25-1.82)     | <0.001| 80.4     | <0.001|
| **Treatment**                    |                |                 |               |                      |       |          |       |
| Surgical resection               | 8              | 3218            | Random        | 1.49 (1.17-1.81)     | <0.001| 82.7     | <0.001|
| TACE                             | 2              | 267             | Random        | 2.20 (1.19-3.22)     | <0.001| 0        | 0.940 |
| Palliative treatments            | 1              | 429             |               | 1.02 (1.01-1.02)     | <0.001|          |       |
| **Staging criteria**             |                |                 |               |                      |       |          |       |
| AJCC/NA                          | 6              | 1960            | Random        | 1.60 (1.38-1.81)     | <0.001| 0        | 0.823 |
| BCLC                             | 5              | 2060            | Random        | 1.56 (1.20-1.91)     | <0.001| 43.3     | 0.133 |
| Milan criteria                   | 1              | 241             |               | 1.02 (1.01-1.02)     | <0.001|          |       |
| **Sample size**                  |                |                 |               |                      |       |          |       |
| <230                             | 4              | 664             | Random        | 1.82 (1.29-2.34)     | <0.001| 0        | 0.701 |
| ≥230                             | 7              | 3250            | Random        | 1.45 (1.14-1.76)     | <0.001| 85.2     | <0.001|
| **Cut-off value of ALRI**        |                |                 |               |                      |       |          |       |
| <26                              | 5              | 1534            | Random        | 1.51 (1.21-1.80)     | <0.001| 31.4     | 0.212 |
| ≥26                              | 6              | 2380            | Random        | 1.54 (1.12-1.96)     | <0.001| 83.3     | <0.001|
| **Cut-off selection**            |                |                 |               |                      |       |          |       |
| ROC analysis                     | 8              | 2501            | Random        | 1.49 (1.31-1.68)     | <0.001| 0        | 0.441 |
| R software                       | 1              | 189             |               | 2.18 (1.30-3.65)     | 0.003 |          |       |
| Mean value                       | 1              | 241             |               | 1.02 (1.01-1.02)     | <0.001|          |       |
| X-tile                           | 1              | 983             |               | 1.76 (1.42-2.17)     | <0.001|          |       |
| **NOS score**                    |                |                 |               |                      |       |          |       |
| <8                               | 2              | 612             | Random        | 1.24 (0.73-1.76)     | <0.001| 84       | 0.012 |
| ≥8                               | 9              | 3302            | Random        | 1.58 (1.37-1.78)     | <0.001| 16.3     | 0.298 |
| **PFS**                          |                |                 |               |                      |       |          |       |
| Total                            | 7              | 2899            | Random        | 1.36 (1.10-1.63)     | <0.001| 81.8     | <0.001|
| **Treatment**                    |                |                 |               |                      |       |          |       |
| Surgical resection               | 6              | 2821            | Random        | 1.35 (1.08-1.61)     | <0.001| 84       | <0.001|
| TACE                             | 1              | 78              |               | 2.21 (1.04-4.71)     | 0.040 |          |       |
| **Staging criteria**             |                |                 |               |                      |       |          |       |
| NA                               | 2              | 787             | Random        | 1.60 (1.31-1.89)     | <0.001| 0        | 0.521 |
| BCLC                             | 4              | 1871            | Random        | 1.37 (1.18-1.55)     | <0.001| 0        | 0.651 |
| Milan criteria                   | 1              | 241             |               | 1.01 (1.01-1.02)     | <0.001|          |       |
| **Sample size**                  |                |                 |               |                      |       |          |       |
| <230                             | 1              | 78              |               | 2.21 (1.04-4.71)     | 0.040 |          |       |
| ≥230                             | 6              | 2821            | Random        | 1.35 (1.08-1.61)     | <0.001| 84       | <0.001|
| **Cut-off value of ALRI**        |                |                 |               |                      |       |          |       |
| <26                              | 4              | 1328            | Random        | 1.48 (1.21-1.74)     | <0.001| 18.7     | 0.297 |
| ≥26                              | 3              | 1571            | Random        | 1.24 (0.92-1.57)     | <0.001| 85.5     | 0.001 |
| **Cut-off selection**            |                |                 |               |                      |       |          |       |
| ROC analysis                     | 5              | 1675            | Random        | 1.46 (1.26-1.66)     | <0.001| 0        | 0.448 |
| Mean value                       | 1              | 241             |               | 1.01 (1.01-1.02)     | <0.001|          |       |
| X-tile                           | 1              | 983             |               | 1.39 (1.17-1.65)     | <0.001|          |       |
| **NOS score**                    |                |                 |               |                      |       |          |       |
| <8                               | 2              | 612             | Random        | 1.22 (0.73-1.70)     | <0.001| 82.9     | 0.016 |
| ≥8                               | 5              | 1524            | Random        | 1.42 (1.25-1.58)     | <0.001| 0        | 0.443 |
characteristics, including sex (male vs. female), age (>60 years vs. ≤60 years), hepatitis B surface antigen (positive vs. negative), alpha-fetoprotein level (>400 vs. ≤400 ng/mL), cirrhosis (yes vs. no), tumor size (≥5 cm vs. <5 cm), tumor number (multiple vs. single), TNM stage (III-IV vs. I-II), portal vein tumor thrombus (yes vs. no), and distant metastasis (yes vs. no). As shown in Table 3, high ALRI was closely associated with male sex (OR 1.32 [95% CI 1.02–1.70]; P = 0.035), presence of cirrhosis (OR 1.68 [95% CI 1.01–2.81]; P = 0.046), larger tumor size (OR 2.25 [95% CI 1.31–3.88]; P < 0.001), presence of portal vein tumor thrombus (OR 2.50 [95% CI 1.52–4.11]; P < 0.001), and distant metastasis (OR 1.72 [95% CI 1.05–2.82]; P = 0.031).

HBsAg: hepatitis B surface antigen; AFP: alpha-fetoprotein; TNM: tumor-node-metastasis; PVTT: portal vein tumor thrombus; OR: odds ratio; CI: confidence interval.

3.5. Sensitivity Analysis. To assess the robustness of the pooled HRs with 95% CI, a sensitivity analysis was performed by sequentially excluding one study at a time from the meta-analysis. The sensitivity analyses indicated that the pooled relationship (i.e., HR) between ALRI and OS was not affected by the removal of any single study (Figure 3(a)). In addition, the results of the sensitivity analyses implied that the overall results of PFS were not significantly altered by the removal of any single study (Figure 3(b)). In other words, results related to OS and PFS in the meta-analysis were robust.

3.6. Publication Bias. Begg’s and Egger’s tests were used to detect the presence of publication bias. As shown in the funnel plots (Figure 4(a)), no significant publication bias (P = 0.533) was observed related to the association between ALRI and OS in the current analysis. However, significant publication bias was noticed based on Egger’s test (P < 0.05). Moreover, the funnel plot of association between ALRI and PFS showed an asymmetry of the result (Figure 4(b); Begg’s test P = 0.548), and a significant publication bias was observed in Egger’s test (P = 0.002).

4. Discussion

Recently, an increasing number of serum markers, such as PNI, SII, neutrophil-to-lymphocyte ratio, and monocyte-to-lymphocyte ratio, have been used in the clinical practice owing to their ready availability and cost-effectiveness [26–28]. Among them, ALRI is a novel combined indicator, although its prognostic value and clinical significance in HCC remain uncertain. To our knowledge, the present meta-analysis was the first to determine the overall prognostic impact and clinical significance in HCC by aggregating available data from nine clinical studies.

The results of our meta-analysis have some clinical implications. Based on the available data (N = 3914), higher ALRI values were associated with inferior survival—for both OS and PFS—in patients with HCC. Our meta-analysis indicated that patients with HCC with increased ALRI had a higher risk for larger tumor size, presence of portal vein tumor thrombus, and distant metastasis, which would shorten survival time. Because of ready availability and low cost, ALRI could be routinely used to monitor disease progression and developing optimal treatment strategies. Individuals with HCC who have higher ALRI before treatment may benefit from radical treatments, such as postoperative adjuvant chemoradiotherapy and/or surgery, than those who have lower ALRI.

Because AST is highly sensitive to damaged liver function, serum AST levels are commonly used to evaluate liver function [29]. Once hepatocytes are damaged/injured, intracellular AST is directly released into the peripheral blood, which leads to increased serum AST levels. Increased AST levels generally imply the activity of HBV in liver cancer patients infected with the virus, and the activity of HBV is a risk factor for decreased survival time in patients with HCC [30]. The close correlation between the pathogenesis of malignant tumor and systemic inflammation is quite common in patients with HCC because most result from
chronic hepatitis [31]. Accumulating evidence has revealed that lymphocytes play a central role in the antitumor immune response [32, 33]. CD4+ T helper 1 cells and CD8+ cytotoxic T lymphocytes can kill HCC cells and effectively prevent oncogenesis and progression of HCC [34]. Hence, increased lymphocyte counts signify a relatively favorable prognosis in individuals with HCC. In summary, elevated serum AST levels are strongly associated with the progression of HCC, and a decrease in lymphocyte count reflects damage to antitumor immunity. Therefore, high ALRI suggests worse prognosis in individuals with HCC.

The survival outcomes of HCC mainly depend on the prognostic biomarkers and staging systems, while it is not sufficient to assess the survival of patients with HCC by these criteria alone, as the survival outcome of HCC is not only affected by the tumor biology but also affected by the individuals’ liver function. So, ALRI seems to be a promising biomarker for patients with HCC. In addition to the prognostic relevance, ALRI also exhibited clinical relevance with significant clinical features, such as distant metastases, portal vein thrombosis, and tumor size greater than 5 cm.

Our meta-analysis had four obvious limitations. First, all eleven included studies were retrospective trials, and no prospective trials were included. Second, all nine studies were performed in China, and the prognostic significance of ALRI in patients with HCC in other countries remains uncertain. Finally, the cut-off values for ALRI varied across the eleven included studies, and the calculation methods were also inconsistent. Lastly, as the original study did not report underlying liver disease (i.e., the presence of cirrhosis, HBV, HCV, or nonalcoholic steatohepatitis), we could not perform subgroup analysis based on this variable. Hence, an updated meta-analysis including more clinical studies from various areas is still needed in the future.

In conclusion, high ALRI in patients with HCC predicted inferior survival outcomes and was strongly associated with some important features that imply tumor progression in HCC. However, more prospective clinical
trials investigating the association between ALRI and survival among HCC patients from diverse ethnicities are necessary to verify this conclusion.

**Data Availability**

The datasets analyzed during this study are available from the corresponding author on reasonable request.

**Conflicts of Interest**

The authors declared that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Authors’ Contributions**

Xiulan Peng, Yali Huang, and Min Zhang contributed equally to this work and are co-first authors.

**Acknowledgments**

This study was supported by the Wuhan Municipal Health Commission (No. WX21D42).

**Supplementary Materials**

Table S1 is the detailed items of Newcastle–Ottawa Scale in this meta-analysis. (Supplementary Materials)

**References**

[1] L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-Tieulent, and A. Jemal, “Global cancer statistics, 2012,” *A Cancer Journal for Clinicians*, vol. 65, no. 2, pp. 87–108, 2015.

[2] R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2019,” *CA: A Cancer Journal for Clinicians*, vol. 69, no. 1, pp. 7–34, 2019.

[3] M. M. Center and A. Jemal, “International trends in liver cancer incidence rates,” *Cancer Epidemiology, Biomarkers & Prevention*, vol. 20, no. 11, pp. 2362–2368, 2011.

[4] R. M. Feng, Y. N. Zong, S. M. Cao, and R. H. Xu, “Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?,” *Cancer Communications*, vol. 39, no. 1, pp. 1–12, 2019.

[5] Y. M. Yang, S. Y. Kim, and E. Seki, “Inflammation and liver cancer: molecular mechanisms and therapeutic targets,” *Seminars in Liver Disease*, vol. 39, no. 1, pp. 026–042, 2019.

[6] Z. Guo, W. Chen, G. Dai, and Y. Huang, “Cordycepin suppresses the migration and invasion of human liver cancer cells by downregulating the expression of CXCR4,” *International Journal of Molecular Medicine*, vol. 45, no. 1, pp. 141–150, 2019.

[7] D. C. Kahraman, T. Kahraman, and R. Cetin-Atalay, “Targeting PI3K/Akt/mTOR pathway identifies differential expression and functional role of IL8 in liver cancer stem cell enrichment,” *Molecular Cancer Therapeutics*, vol. 18, no. 11, pp. 2146–2157, 2019.

[8] B. Wang, Y. Huang, and T. Lin, “Prognostic impact of elevated pre-treatment systemic immune-inflammation index (SII) in hepatocellular carcinoma,” *Medicine*, vol. 99, no. 1, article e18571, 2020.

[9] D. Wang, X. Hu, L. Xiao et al., “Prognostic nutritional index and systemic immune-inflammation index predict the prognosis of patients with HCC,” *Journal of Gastrointestinal Surgery*, vol. 25, no. 2, pp. 421–427, 2021.

[10] Y. Yang, M. C. Wang, T. Tian et al., “A high preoperative platelet-lymphocyte ratio is a negative predictor of survival after liver resection for hepatitis B virus-related hepatocellular carcinoma: a retrospective study,” *Frontiers in Oncology*, vol. 10, article 576205, 2020.

[11] S. L. Chan, L. L. Wong, K. A. Chan et al., “Development of a novel inflammation-based index for hepatocellular carcinoma,” *Liver Cancer*, vol. 9, no. 2, pp. 167–181, 2020.

[12] A. Casadei Gardini, F. G. Foschi, F. Conti et al., “Immune inflammation indicators and ALBI score to predict liver cancer in HCV- patients treated with direct-acting antivirals,” *Digestive and Liver Disease*, vol. 51, no. 5, pp. 681–688, 2019.

[13] C. He, W. Peng, C. Li, and T. F. Wen, “Postoperative aspartate aminotransferase to lymphocyte ratio index change is an independent predictor of survival in patients with small hepatocellular carcinoma,” *Medicine*, vol. 96, no. 45, article e8540, 2017.

[14] K. Liu, Y. Lv, Y. Niu, and Y. Bu, “Prognostic value of γ-glutamyl transpeptidase to albumin ratio combined with aspartate aminotransferase to lymphocyte ratio in patients with hepatocellular carcinoma after hepatectomy,” *Medicine*, vol. 99, no. 48, article e23339, 2020.

[15] J. Jin, P. Zhu, Y. Liao, J. Li, W. Liao, and S. He, “Elevated preoperative aspartate aminotransferase to lymphocyte ratio index as an independent prognostic factor for patients with hepatocellular carcinoma after hepatic resection,” *Oncotarget*, vol. 6, no. 22, pp. 19217–19227, 2015.

[16] Z. Yang, J. Zhang, Y. Lu et al., “Aspartate aminotransferase-lymphocyte ratio index and systemic immune-inflammation index predict overall survival in HBV-related hepatocellular carcinoma patients after transcatheter arterial chemoembolization,” *Oncotarget*, vol. 6, no. 40, pp. 43090–43098, 2015.

[17] L. Zhao, D. Yang, X. Ma et al., “The prognostic value of aspartate aminotransferase to lymphocyte ratio and systemic immune-inflammation index for overall survival of hepatocellular carcinoma patients treated with palliative treatments,” *Journal of Cancer*, vol. 10, no. 10, pp. 2299–2311, 2019.

[18] M. Zheng, B. Gao, and X. Z. Peng, “Effect of aspartate aminotransferase to lymphocyte ratio on prognosis of liver cancer patients before TACE,” *Medical Innovation of China*, vol. 16, no. 1, pp. 5–10, 2019.

[19] L. Y. Luo, “Establishment and Verification of a Model for Postoperative Recurrence of Hepatocellular Carcinoma,” Guilin Medical University, 2019.

[20] M. Qin, C. Si, X. Y. Chen, Y. Deng, and H. H. Yao, “The value of preoperative ratio of glutamate transaminase to lymphocyte in the prognosis evaluation of R0 resection of primary hepatocellular carcinoma, *Sichuan Medical Journal*, vol. 40, no. 1, pp. 38–43, 2019.

[21] Y. Chen, C. He, T. Wen, L. Yan, and J. Yang, “The prognostic value of aspartate aminotransferase-to-lymphocyte ratio index in early-stage hepatocellular carcinoma after hepatectomy: a propensity-score matched analysis,” *Asia-Pacific Journal of Clinical Oncology*, vol. 17, no. 5, 2021.

[22] M. Sun, J. Qin, Q. Zhang et al., “A novel post-operative ALRI model accurately predicts clinical outcomes of resected hepatocellular carcinoma Patients,” *Oncologia*, vol. 11, article 665497, 2021.
[23] W. Wu, Q. Wang, D. Han et al., “Prognostic value of preoperative inflammatory markers in patients with hepatocellular carcinoma who underwent curative resection,” Cancer Cell International, vol. 21, no. 1, 2021.

[24] L. Shamseer, D. Moher, M. Clarke et al., “Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation,” British Medical Journal, vol. 349, article g7647, 2015.

[25] A. Stang, “Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses,” European Journal of Epidemiology, vol. 25, no. 9, pp. 603–605, 2010.

[26] R. Cong, F. Kong, J. Ma, Q. Li, Q. Wu, and X. Ma, “Combination of preoperative neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and monocyte-lymphocyte ratio: a superior prognostic factor of endometrial cancer,” BMC Cancer, vol. 20, no. 1, p. 464, 2020.

[27] Y. Zhang, G. Xiao, and R. Wang, “Clinical significance of systemic immune-inflammation index (SII) and C-reactive protein-to-albumin ratio (CAR) in patients with esophageal cancer: a meta-analysis,” Cancer Management and Research, vol. 11, pp. 4185–4200, 2019.

[28] J. Gao, Y. Wang, F. Li et al., “Prognostic nutritional index and neutrophil-to-lymphocyte ratio are respectively associated with prognosis of gastric cancer with liver metastasis undergoing and without hepatectomy,” Biomed Research International, vol. 2019, Article ID 4213623, 7 pages, 2019.

[29] J. Ahn, D. W. Jun, H. Y. Lee, and J. H. Moon, “Critical appraisal for low-carbohydrate diet in nonalcoholic fatty liver disease: review and meta-analyses,” Clinical Nutrition, vol. 38, no. 5, pp. 2023–2030, 2019.

[30] C. D. Witjes, J. N. IJzermans, A. A. van der Eijk, B. E. Hansen, C. Verhoef, and R. A. De Man, “Quantitative HBV DNA and AST are strong predictors for survival after HCC detection in chronic HBV patients,” Netherlands Journal of Medicine, vol. 69, no. 11, pp. 508–513, 2011.

[31] H. B. el-Serag and K. L. Rudolph, “Hepatocellular carcinoma: epidemiology and molecular carcinogenesis,” Gastroenterology, vol. 132, no. 7, pp. 2557–2576, 2007.

[32] C. Zheng, L. Zheng, J. K. Yoo et al., “Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing,” Cell, vol. 169, no. 7, pp. 1342–1356.e16, 2017.

[33] F. Pages, J. Galon, M. C. Dieu-Nosjean, E. Tartour, C. Sautes-Fridman, and W. H. Fridman, “Immune infiltration in human tumors: a prognostic factor that should not be ignored,” Oncogene, vol. 29, no. 8, pp. 1093–1102, 2010.

[34] V. Chew, J. Chen, D. Lee et al., “Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma,” Gut, vol. 61, no. 3, pp. 427–438, 2012.